• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Hip and Knee News

News Resource About Hip, Knee and Orthopedic Surgery

medical care alert
  • Home
  • Hip Surgery
  • Knee Surgery
  • Resources
    • Hip and Knee Glossary
  • About/Contact

Stronger Antiplatelet Better for VTE Prophylaxis After Joint Replacement

by

Enoxaparin bested aspirin for preventing symptomatic venous thromboembolism (VTE) after total hip or total knee arthroplasty when used without initial anticoagulation in the CRISTAL randomized trial.

These events occurred within 90 days of surgery in 3.45% of aspirin-treated patients compared with 1.82% of enoxaparin-treated patients, which didn’t hit noninferiority criteria but did show significant superiority for enoxaparin (P=0.007).

That primary endpoint advantage was driven by a 1.61-percentage point lower rate of deep vein thrombosis (DVT), specifically below-the-knee cases.

No significant differences emerged between groups for above-knee DVT or pulmonary embolism, Verinder S. Sidhu, MS, of the Ingham Institute for Applied Medical Research in Liverpool, Australia, and colleagues reported in JAMA.

In interpreting the study findings, the group cautioned that “below-knee DVT represents a less clinically important form of VTE compared with above-knee DVT or pulmonary embolism, and the clinical importance of these findings remains uncertain.”

Given similarly low incidences of major thromboembolic events and mortality, the results are unlikely to convince clinicians who use aspirin prophylaxis to switch, noted Noel C. Chan, MD, and Mohit Bhandari, MD, PhD, both of McMaster University in Hamilton, Ontario, in an accompanying editorial.

“Reducing nonfatal VTE is important, but any benefits with thromboprophylaxis require a trade-off with bleeding risk, costs to the health care system, and convenience to patients, all of which make aspirin particularly attractive for thromboprophylaxis,” they wrote.

In the CRISTAL trial, none of the six secondary outcomes came out different for enoxaparin versus aspirin, including mortality, major bleeding, 90-day readmission or reoperation, reoperation within 6 months, and drug adherence.

A recent large randomized clinical trial from Canada reported noninferiority of aspirin to rivaroxaban (Xarelto) for VTE prophylaxis after total hip or knee arthroplasty. “However, both groups received rivaroxaban for 5 days prior to randomization to either aspirin or continued rivaroxaban,” noted Sidhu’s group.

CRISTAL took that one step further for 9,711 adults (median age 68, 56.8% women) undergoing total hip or knee arthroplasty for osteoarthritis who were not getting preoperative anticoagulation. The 31 participating hospitals in Australia were cluster-randomized within a national registry to give aspirin 100 mg daily or enoxaparin 40 mg daily (except for those with underweight and poor kidney function) as the sole antithrombotic prophylaxis following a standardized protocol for a specified period before crossing over to the other agent.

Both regimens started within 24 hours of surgery and were continued for 35 days after hip arthroplasty and for 14 days after knee arthroplasty. Intraoperative and postoperative intermittent pneumatic compression calf devices were also used universally, along with compression stockings and mobilization on day 0 or day 1 postoperatively.

However, an important limitation was that the study was terminated early at 62% of the planned enrollment of 15,562.

The editorialists pointed out that this “reduced the power to detect differences in clinically important VTE,” and the researchers acknowledged that the study might not have been powered to detect certain significant between-group differences, specifically the numerically higher rate of pulmonary embolism in the aspirin group (1.1% vs 0.6% with enoxaparin, P=0.17).

Another issue, the editorialists wrote, was “the potential for diagnostic suspicion bias in patients taking aspirin because physicians making the decision to perform leg ultrasound or lung imaging were not masked to the assigned prophylactic treatment.”

The researchers added that another potential influence on the findings was that the 15% of people taking aspirin before the trial stayed on it, such that the group randomized to enoxaparin continued aspirin in addition to enoxaparin, whereas the aspirin group didn’t take additional aspirin.

They suggested that a cost-effectiveness analysis might be warranted “to better understand the clinical relevance of the trial results.”

Disclosures

The study was funded by the Australian government.

Sidhu disclosed no relevant conflicts of interest. Co-authors reported multiple relationships with industry.

Chan reported receiving personal fees from Stago and Boehringer Ingelheim.

###
Originally Appeared Here

Filed Under: ORTHO NEWS, ortho news - Google

Primary Sidebar

Make It Easier to Get In and Out of Bed

sleep to stand bed

ORTHO NEWS

Patients with late-stage knee OA incur high costs for nonoperative treatments before total knee arthroplasty

A Road to Recovery After Knee Surgery: 6 Tips to Follow

High costs of nonoperative treatment in the year before total knee replacement

Joint replacement maker Stryker to create 600 new jobs in Cork

Knee pain: When is it wise to go for knee replacement surgery?

Myongji upgrades joint replacement precision with surgical robot < Hospital < 기사본문

Are you planning to have a knee or hip replacement?  | McLaren Health Care News

Ankle injuries: Q&A with Scripps orthopedic surgeon Jacob Braunstein

Diversity in orthopedic leadership made minimal progress from 2007 to 2019

2 Hartford HealthCare hospitals lauded for total hip, knee replacement

Expert Article: CUVIS Joint, Your Robotic Doctor: Read About World’s First Active Robotic Knee Replacement System

Orthopedic Institute of Southern Illinois celebrates growth of its surgery center | Healthcare

Copyright © 2023 · DISCLAIMER: Nothing here constitutes legal, medical, or other advice; all content relates to an individual perspective only. A professional relationship with a physician, or with a lawyer is built over time, with mutual investment, trust, and respect. This site is not a substitute for that.
~ THIS DOMAIN IS FOR SALE ~

Privacy Policy